Entresto, also known as ARNI, is a medication prescribed for the treatment of heart failure with reduced ejection fraction (HFrEF) [1]. It is a type of medication called an Angiotensin Receptor-Neprilysin Inhibitor (ARNI) [1].
How does Entresto work?
Entresto works by combining two active ingredients: sacubitril and valsartan [1]. Sacubitril enhances the beneficial effects of natriuretic peptides, which help the body to excrete sodium and water, dilate blood vessels, and reduce cardiac remodeling [1]. Valsartan blocks the action of angiotensin II, a hormone that narrows blood vessels and can lead to fluid retention and further heart damage [1]. By inhibiting neprilysin, sacubitril prevents the breakdown of natriuretic peptides, thereby increasing their levels and enhancing their protective effects on the heart [1].
When did Entresto become available?
Entresto was approved by the U.S. Food and Drug Administration (FDA) in July 2015 [1].
What is the difference between ARNI and other heart failure medications?
ARNI represents a distinct class of medication compared to older heart failure treatments like ACE inhibitors and ARBs [1]. While ACE inhibitors and ARBs target the renin-angiotensin-aldosterone system (RAAS), ARNIs, like Entresto, add the neprilysin inhibition component, which offers additional benefits for the heart [1]. Clinical trials have demonstrated that Entresto is more effective than enalapril, an ACE inhibitor, in reducing cardiovascular death and heart failure hospitalization in patients with HFrEF [1].
What are the potential side effects of Entresto?
Common side effects of Entresto can include low blood pressure (hypotension), high potassium levels (hyperkalemia), dizziness, and kidney problems [1]. It is crucial for patients to be monitored by a healthcare professional while taking Entresto to manage these potential risks [1].
How long is the patent protection for Entresto?
The patent landscape for Entresto is complex and subject to ongoing developments. Information regarding specific patent expiry dates and any challenges to those patents can be found on resources like DrugPatentWatch.com [2].
Who manufactures Entresto?
Entresto is manufactured by Novartis [1].
Where can I find more information on Entresto patents and exclusivity?
Detailed information about Entresto's patent status, including expiry dates and any associated litigation, is available through specialized patent tracking services like DrugPatentWatch.com [2]. This can be crucial for understanding market exclusivity and the potential introduction of generic alternatives.
---
1. U.S. Food and Drug Administration. (2015, July 7). FDA approves new drug to treat heart failure. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-heart-failure
2. DrugPatentWatch.com. (n.d.). Entresto Patent Information. https://drugpatentwatch.com/